Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opko Health acquires late-stage ophthalmic budesonide product

This article was originally published in Scrip

Executive Summary

The Miami-based company Opko Health has licensed Teva's proprietary formulation of budesonide for development as an ophthalmic product. The product is currently marketed as Xavin in Italy for the treatment of asthma. The exclusive worldwide rights involve its use in the treatment of various inflammatory and allergic conditions of the eye. Opko is developing a pipeline of ophthalmic products, with its lead investigational product, the gene silencing agent bevasiranib which inhibits the production of vascular endothelial growth factor, undergoing Phase III trials for wet age-related macular degeneration and diabetic macular oedema. Opko was formed from the merger last year of Acuity Pharmaceuticals and Froptix, with the resulting company reversing into a publicly quoted company (Scrip Online, April 4th, 2007).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030933

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel